TransCode Therapeutics, Inc. (NasdaqCM: RNAZ)
Health Care · Biotechnology · US
$1.70
-8.60% today · -88.5% 1Y
TransCode Therapeutics, Inc. (NasdaqCM: RNAZ) operates in the Biotechnology industry within the Health Care sector. The company is valued at $28.78M and employs 12 people.
Over the last twelve months the share price has lost 88.5%, trading between 1.52 and 15.39.
Tweenvest scores TransCode Therapeutics, Inc. across four factors: quality 49/100, value 90/100. Its strongest factor is value.
RNAZ price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $28.78M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -51.08
- Dividend yield
- —
- Beta (5Y)
- 1.26
- 52-week high
- $15.39
- 52-week low
- $1.52
- Avg volume (3M)
- —
- Shares outstanding
- 16.93M
- Employees
- 12
- Next earnings
- —
About TransCode Therapeutics, Inc.
TransCode Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering and marketing therapeutic agents and diagnostic tools specifically aimed at combating and detecting metastatic disease. Central to its pipeline is TTX-MC138, a lead therapeutic compound currently undergoing preclinical evaluation for its potential in treating advanced, spreading cancers. Beyond its primary candidate, the company's preclinical portfolio also features TTX-siPDL1, an siRNA designed to modulate programmed death-ligand 1, and TTX-siLIN28B, another siRNA that inhibits the RNA-binding protein LIN28B. TransCode also pursues several cancer-agnostic initiatives. These encompass TTX-RIGA, an RNA-based agent engineered to stimulate the RIG-I immune pathway within the tumor's immediate surroundings; TTX-CRISPR, a gene-editing platform utilizing CRISPR/Cas9 technology to correct or eradicate oncogenic genes within cancer cells; and TTX-mRNA, an innovative mRNA platform dedicated to creating cancer vaccines that incite powerful cytotoxic immune reactions against malignant cells. Established in 2016, TransCode Therapeutics is headquartered in Boston, Massachusetts.
- ISIN
- US89357L5012
- Founded
- 2016
- Listed since
- Jul 8, 2021
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Medicenna Therapeutics Corp.TSX: MDNA | $29.36M | CA$0.45 | +3.45% |
| Quratis Inc.KOSDAQ: A348080 | $29.12M | ₩3,310.00 | -11.50% |
| Microbix Biosystems Inc.TSX: MBX | $29.05M | CA$0.30 | -3.23% |
| CEL-SCI CorporationNYSEAM: CVM | $28.85M | $1.64 | +1.86% |
| Amplia Therapeutics LimitedASX: ATX | $28.57M | AU$0.08 | -23.81% |
| NextCure, Inc.NasdaqGS: NXTC | $28.56M | $6.24 | -13.09% |
| Intervacc AB (publ)OM: IVACC | $28.25M | Skr0.82 | -7.44% |
| Matricelf LtdTASE: MTLF | $27.79M | ₪2.60 | +4.20% |
Figures last refreshed Oct 18, 2026.